Following transduction of the third-generation CAR (CAR-TIM-3) containing TIM-3 single-chain fragment variable (scFv), CD28, 4-1BB, and CD3ζ into human NK-92 cells, these engineered cells effectively recognize and target TIM-3-positive cells, exhibiting significant antitumor activity against various primary AML cell lines, successfully inhibiting in vitro leukemia clone proliferation while exerting minimal impact on hematopoietic stem progenitor cells. Here, HAVCR2 is linked to acute myeloid leukemia.